Logo image of ALMS

ALUMIS INC (ALMS) Stock Fundamental Analysis

NASDAQ:ALMS - Nasdaq - US0223071020 - Common Stock - Currency: USD

5.67  -0.92 (-13.96%)

After market: 5.95 +0.28 (+4.94%)

Fundamental Rating

2

Taking everything into account, ALMS scores 2 out of 10 in our fundamental rating. ALMS was compared to 195 industry peers in the Pharmaceuticals industry. ALMS has a great financial health rating, but its profitability evaluates not so good. ALMS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALMS has reported negative net income.
ALMS Yearly Net Income VS EBIT VS OCF VS FCFALMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -85.92%, ALMS is not doing good in the industry: 74.73% of the companies in the same industry are doing better.
With a Return On Equity value of -101.74%, ALMS perfoms like the industry average, outperforming 40.32% of the companies in the same industry.
Industry RankSector Rank
ROA -85.92%
ROE -101.74%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMS Yearly ROA, ROE, ROICALMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 -100 -200 -300 -400

1.3 Margins

ALMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALMS Yearly Profit, Operating, Gross MarginsALMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

ALMS has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for ALMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALMS Yearly Shares OutstandingALMS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 10M 20M 30M 40M 50M
ALMS Yearly Total Debt VS Total AssetsALMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -0.44, we must say that ALMS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.44, ALMS perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
There is no outstanding debt for ALMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.44
ROIC/WACCN/A
WACCN/A
ALMS Yearly LT Debt VS Equity VS FCFALMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 0 50M -50M -100M

2.3 Liquidity

ALMS has a Current Ratio of 11.26. This indicates that ALMS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ALMS (11.26) is better than 84.95% of its industry peers.
ALMS has a Quick Ratio of 11.26. This indicates that ALMS is financially healthy and has no problem in meeting its short term obligations.
ALMS has a better Quick ratio (11.26) than 84.95% of its industry peers.
Industry RankSector Rank
Current Ratio 11.26
Quick Ratio 11.26
ALMS Yearly Current Assets VS Current LiabilitesALMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

ALMS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.47%.
EPS 1Y (TTM)-38.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALMS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -13.75% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-191.49%
EPS Next 2Y-29.54%
EPS Next 3Y-13.75%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALMS Yearly Revenue VS EstimatesALMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026
ALMS Yearly EPS VS EstimatesALMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALMS. In the last year negative earnings were reported.
Also next year ALMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMS Price Earnings VS Forward Price EarningsALMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALMS Per share dataALMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 -6

4.3 Compensation for Growth

ALMS's earnings are expected to decrease with -13.75% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.54%
EPS Next 3Y-13.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALMS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALUMIS INC

NASDAQ:ALMS (2/7/2025, 8:11:20 PM)

After market: 5.95 +0.28 (+4.94%)

5.67

-0.92 (-13.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners50.57%
Inst Owner Change0.04%
Ins Owners1.2%
Ins Owner Change0%
Market Cap308.50M
Analysts86.67
Price Target30.6 (439.68%)
Short Float %6.24%
Short Ratio15.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-125.92%
Min EPS beat(2)-249.36%
Max EPS beat(2)-2.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)-6.75
EYN/A
EPS(NY)-5.02
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS6.4
TBVpS6.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -85.92%
ROE -101.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.26
Quick Ratio 11.26
Altman-Z -0.44
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-191.49%
EPS Next 2Y-29.54%
EPS Next 3Y-13.75%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-38.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-74.84%
EBIT Next 3Y-19.14%
EBIT Next 5YN/A
FCF growth 1Y-22.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.66%
OCF growth 3YN/A
OCF growth 5YN/A